Special Issue

Advances in Nanoparticle-Based Drug Delivery Systems for Tumor-Targeted Combination Treatment

Message from the Guest Editors

In this Special Issue, we will focus on recent advances in tumor-targeted combination therapy strategies based on the design of nano-drug delivery systems. The complexity and heterogeneity of tumors result in critical obstacles that severely impede treatment efficiency. Therefore, it is impossible to eliminate drug-resistant tumors and prevent cancer metastasis using a single treatment modality. Nanomedicine-mediated combination therapies provide promising approaches to synergistically potentiating the therapeutic efficacy of treatments against malignancies or to exerting superadditive (namely "1 + 1 > 2") effects that are stronger than those of any monotherapy or their theoretical combinations. This Special Issue aims to publish high-quality research papers and reviews focusing on the design, synthesis, and applications of nanomedicines for tumor multimodal synergistic therapy. Both original research articles and reviews are welcome. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Zifu Li

1. National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
2. Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
3. Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medical, Huazhong University of Science and Technology, Wuhan 430074, China
4. Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, Huazhong University of Science and Technology, Wuhan 430074, China

Dr. Xiao Dong

Department of Pharmacy, School of Medicine, Shanghai University, Shanghai 200444, China

Deadline for manuscript submissions

closed (31 August 2024)

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/181971

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

MDPI

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).